Abstract: The present application provides a vibration test bench for a permanent maglev train, which comprises: a base, a vertical excitation system, a permanent magnet track simulation system, a gantry-type supporting frame, a suspension platform, a lateral excitation system and a longitudinal excitation system. In the present application, the positional relationship among the levitation frame of the permanent maglev train, the suspension platform and the permanent magnet track simulation system is adjusted by means of the vertical excitation system, the lateral excitation system and the vertical excitation system respectively, the permanent maglev train is maintained in the levitated state by means of the permanent magnet track simulation system, and a variety of the working conditions, such as unsmooth passing on the track, etc., are simulated by means of the vertical excitation system and the lateral excitation system respectively.

Abstract: The present invention discloses an application of a medical cell CMU-pb-7 in preparation of blood lipid-lowering drugs, which belongs to the technical field of biology. The medical cell CMU-pb-7 disclosed by the present invention is a newly discovered strain of Lactobacillus rhamnosus, having a collection number of CCTCC NO: M 2022220. The medical cell CMU-pb-7 of the present invention can relieve impaired glucose tolerance caused by a high-fat diet in mice with hyperlipidemia, reduce the blood lipid level, enhance the antioxidant capacity of the liver tissue, and regulate the expression of key proteins of liver lipid metabolism to relieve fatty change caused by a high-fat diet. The medical cell CMU-pb-7 disclosed by the present invention has a great potential application prospect in preparation of blood lipid-lowering drugs.

Abstract: The present invention discloses a medical cell CMU-pb-7 and an application thereof in preparation of antioxidant drugs, which belongs to the technical field of biology. The medical cell CMU-pb-7 disclosed by the present invention is a newly isolated and screened strain of Lactobacillus rhamnosus, having a collection number of CCTCC NO: M 2022220. The medical cell CMU-pb-7 of the present invention can enhance the antioxidant capacity of liver tissue, reduce the oxidative stress level, relieve the pathological changes of liver fat, regulate the oxidative stress level in intestinal tract, and relieve the oxidative damage to the ileum of high-fat mice. The medical cell CMU-pb-7 disclosed by the present invention has a great potential application prospect in preparation of antioxidant drugs.

Abstract: The present invention discloses an application of a medical cell CMU-pb-7 in preparation of blood lipid-lowering drugs, which belongs to the technical field of biology. The medical cell CMU-pb-7 disclosed by the present invention is a newly discovered strain of Lactobacillus rhamnosus, having a collection number of CCTCC NO: M 2022220. The medical cell CMU-pb-7 of the present invention can relieve impaired glucose tolerance caused by a high-fat diet in mice with hyperlipidemia, reduce the blood lipid level, enhance the antioxidant capacity of the liver tissue, and regulate the expression of key proteins of liver lipid metabolism to relieve fatty change caused by a high-fat diet. The medical cell CMU-pb-7 disclosed by the present invention has a great potential application prospect in preparation of blood lipid-lowering drugs.

Abstract: A strain of Lactobacillus paracasei L.p R3-10 and its application in preparation of medicine for treating ulcerative colitis are disclosed. The Lactobacillus paracasei R3-10 of the present disclosure is a Lactobacillus induced by a low nutritional gradient tolerance, it is obtained after L.p R3 has been domesticated by starvation for 10 generations, and its preservation number is CGMCC No. 19520. The L.p R3-10 of the present disclosure can be prepared as a medicine for treating ulcerative colitis.